Eris Lifesciences Stock Screener | Share Price & Fundamental Analysis
ERIS
Pharmaceuticals
Screen Eris Lifesciences share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹1542.00
▲
8.50 (0.55%)
Share Price BSE
₹1551.80
▲
9.80 (0.64%)
Market Cap
₹20,326.28 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
6.63
EPS (TTM)
₹25.85
Dividend Yield
0.49%
Debt to Equity
0.97
52W High
₹1847.70
52W Low
₹1153.10
Operating Margin
36.00%
Profit Margin
14.35%
Revenue (TTM)
₹711.00
EBITDA
₹258.00
Net Income
₹102.00
Total Assets
₹7,033.00
Total Equity
₹3,272.00
Eris Lifesciences Share Price History - Stock Screener Chart
Screen ERIS historical share price movements with interactive charts. Analyze price trends and patterns.
Eris Lifesciences Company Profile - Fundamental Screener
Screen Eris Lifesciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ERIS shares.
Eris Lifesciences Limited is an Indian company that manufactures and markets pharmaceutical products. Founded in 2007, the company operates a manufacturing plant in Guwahati, Assam. Eris focuses on chronic, sub-chronic, and acute therapeutic areas, including cardiovascular, anti-diabetics, vitamins, gastroenterology, and anti-infective. The company has a portfolio of 112 Mother Brands and a distribution network of 22 sales depots, 2,059 stockists, and over 500,000 retail chemists. Eris has expanded through acquisitions and launches of new divisions. It has five wholly-owned subsidiaries and has acquired various brands and businesses in recent years, including dermatology and cosmetology brands. The company also produces human insulin and has entered the anti-thrombotics segment.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Amit Indubhushan Bakshi
ISIN
INE406M01024
Website
https://www.eris.co.in
Eris Lifesciences Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen ERIS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 7,033 | 7,041 | 3,667 | 2,272 | 1,835 | 1,552 | 1,554 | 1,460 | 727 | 398 |
| Current Assets | 1,223 | 2,302 | 765 | 627 | 467 | 480 | 582 | 299 | 216 | 237 |
| Fixed Assets | 5,307 | 4,319 | 2,568 | 918 | 854 | 875 | 761 | 771 | 232 | 65 |
| Liabilities | ||||||||||
| Total Liabilities | 7,033 | 7,041 | 3,667 | 2,272 | 1,835 | 1,552 | 1,554 | 1,460 | 727 | 398 |
| Current Liabilities | 2,380 | 1,286 | 1,003 | 164 | 91 | 91 | 79 | 349 | 60 | 25 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 3,272 | 3,222 | 2,221 | 1,908 | 1,576 | 1,296 | 1,169 | 886 | 591 | 302 |
| Share Capital | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 0 |
| Reserves & Surplus | 2,841 | 2,573 | 2,182 | 1,894 | 1,563 | 1,283 | 1,137 | 848 | 553 | 302 |
Screen ERIS income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 711 | 775 | 793 | 562 | 717 | 744 | 726 | 398 | 461 | 504 | 488 | 309 | 395 | 461 | 420 |
| Expenses | 453 | 496 | 504 | 403 | 470 | 477 | 477 | 284 | 297 | 324 | 311 | 209 | 269 | 309 | 286 |
| EBITDA | 258 | 279 | 289 | 160 | 248 | 267 | 249 | 114 | 164 | 180 | 177 | 100 | 125 | 151 | 134 |
| Operating Profit % | 36.00% | 36.00% | 36.00% | 26.00% | 34.00% | 35.00% | 34.00% | 28.00% | 35.00% | 35.00% | 36.00% | 31.00% | 31.00% | 32.00% | 32.00% |
| Depreciation | 77 | 71 | 69 | 54 | 76 | 81 | 81 | 35 | 41 | 42 | 46 | 18 | 23 | 29 | 30 |
| Interest | 54 | 49 | 50 | 33 | 60 | 60 | 57 | 9 | 17 | 16 | 18 | 1 | 7 | 7 | 3 |
| Profit Before Tax | 129 | 161 | 173 | 77 | 116 | 129 | 116 | 76 | 113 | 126 | 116 | 85 | 101 | 121 | 107 |
| Tax | 27 | 36 | 38 | -3 | 26 | 33 | 29 | 14 | 19 | 4 | 14 | 5 | 8 | 2 | 6 |
| Net Profit | 102 | 125 | 135 | 80 | 90 | 96 | 87 | 62 | 94 | 122 | 102 | 80 | 93 | 119 | 100 |
| EPS | 6.90 | 8.66 | 8.82 | 5.22 | 6.11 | 6.73 | 6.16 | 4.81 | 6.97 | 9.08 | 7.55 | 5.91 | 6.96 | 8.84 | 7.49 |
Eris Lifesciences Cash Flow Screener - Liquidity Fundamentals
Screen ERIS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1,065 | 486 | 292 | 378 | 375 | 271 | 223 | 235 | 200 | 132 |
| Investing Activities | -78 | -1,828 | -975 | -320 | -323 | 123 | -5 | -590 | -185 | -44 |
| Financing Activities | -881 | 1,380 | 688 | -45 | -82 | -335 | -221 | 363 | -24 | -84 |
| Net Cash Flow | 106 | 38 | 5 | 14 | -30 | 60 | -3 | 8 | -8 | 4 |
Screen ERIS shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 54.85% | 54.83% | 54.85% | 54.90% | 54.88% | 54.87% | 54.86% | 52.86% |
| FII Holding | 8.43% | 8.40% | 7.21% | 14.27% | 14.59% | 8.01% | 8.35% | 0.00% |
| DII Holding | 18.07% | 18.17% | 19.36% | 15.63% | 16.23% | 18.64% | 18.06% | 10.02% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 9.16% | 9.12% | 9.12% | 14.24% | 13.53% | 10.51% | 9.29% | 21.66% |
| Other Holding | 9.49% | 9.47% | 9.45% | 0.95% | 0.77% | 7.96% | 9.43% | 15.46% |
| Shareholder Count | 50,087 | 52,225 | 59,438 | 51,753 | 44,176 | 46,346 | 53,314 | 45,931 |
Eris Lifesciences Dividend Screener - Share Yield Analysis
Screen ERIS dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹7.35 | 0.49% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹7.35 | 0.87% |
| 2022-March | ₹6.01 | 1.05% |
| 2021-March | ₹5.50 | 0.80% |
| 2020-March | ₹2.87 | 0.47% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Eris Lifesciences Index Membership - Market Screener Classification
Screen ERIS by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Eris Lifesciences Market Events Screener - Corporate Actions
Screen ERIS market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -9.79% | ||
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -0.28% |
| 2025-08-05 | 2025-08-05 | Quarterly Result Announcement | NA | 0.55% |
| 2025-07-25 | 2025-07-25 | Annual General Meeting | NA | 6.02% |
| 2025-05-19 | 2025-05-19 | Quarterly Result Announcement | NA | 4.50% |
| 2025-02-13 | 2025-02-13 | Dividend | ₹ 7.35 /share | -10.84% |
| 2025-02-04 | 2025-02-04 | Quarterly Result Announcement | NA | 7.78% |
| 2024-10-25 | 2024-10-25 | Quarterly Result Announcement | NA | -3.52% |
| 2022-08-11 | 2022-08-16 | Dividend | ₹ 7.35 /share | -0.23% |
| 2021-08-05 | 2021-08-06 | Dividend | ₹ 6.01 /share | 0.77% |
Eris Lifesciences Competitors Screener - Peer Comparison
Screen ERIS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,134 | 39.35 | 54,729 | 9.71% | 10,980 | 38.94 |
| Divis Laboratories | 169,024 | 68.31 | 9,712 | 18.67% | 2,191 | 47.61 |
| Torrent Pharmaceuticals | 130,024 | 60.76 | 11,539 | 6.99% | 1,911 | 63.27 |
| Cipla | 121,432 | 22.46 | 28,410 | 7.12% | 5,291 | 50.85 |
| Dr Reddys Laboratories | 104,379 | 18.49 | 33,741 | 16.73% | 5,725 | 53.02 |
| Lupin | 95,718 | 22.19 | 22,910 | 13.74% | 3,306 | 57.47 |
| Zydus Life Science | 91,844 | 18.30 | 23,511 | 18.55% | 4,615 | 43.59 |
| Mankind Pharma | 89,579 | 51.11 | 12,744 | 20.90% | 2,007 | 49.10 |
| Aurobindo Pharma | 68,424 | 20.05 | 32,346 | 9.43% | 3,484 | 45.26 |
| Alkem Laboratories | 65,151 | 27.31 | 13,458 | 3.70% | 2,216 | 41.76 |
Eris Lifesciences Company Announcements - News Screener
Screen ERIS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-05 | Closure of Trading Window | View |
| 2026-01-02 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | View |
| 2026-01-02 | Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot | View |
| 2025-12-18 | Announcement under Regulation 30 (LODR)-Cessation | View |
| 2025-12-17 | Second Corrigendum To The Notice Of Postal Ballot Dated November 24 2025 | View |
| 2025-12-15 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-10 | Clarification With Respect To Increase In Volume | View |
| 2025-12-10 | Clarification sought from Eris Lifesciences Ltd | - |
| 2025-12-05 | Corrigendum To The Notice Of Postal Ballot Dated November 24 2025 | View |
| 2025-12-03 | Corporate Presentation | View |
| 2025-11-26 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-24 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | View |
| 2025-11-24 | Announcement under Regulation 30 (LODR)-Acquisition | View |
| 2025-11-24 | Announcement under Regulation 30 (LODR)-Issue of Securities | View |
| 2025-11-24 | Board Meeting Outcome for Meeting Dated November 24 2025 | View |
| 2025-11-19 | Board Meeting Intimation for Issuance Of Equity Shares Of The Company By Way Of A Preferential Issue | View |
| 2025-11-17 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | View |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |